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cancer (melanoma, SCC, and BCC).
However, although all the studies on
melanomas were conducted in Cauca-
sians and classified as high quality,
significant between-study heterogeneity
was still detected in melanomas sub-
group (Table 4 in the article). A more
precise analysis stratified by grade of
melanoma, SCC, and BCC may be
helpful to reach a more definitive
conclusion (of course, unknown factors
may account for the heterogeneity). In
addition, the authors’ Table 2 shows
that 15 case–control studies encom-
passed 6,363 subjects (2,861 cases
and 3,502 controls), but Table 3 lists
the total sample size of 15 case–control
studies as 6,362 (2,860 cases and 3,502
controls).
Overall, the meta-analysis suggests
that the TP53 Arg72Pro polymorphism
may have little involvement in the
pathogenesis of skin cancer, mainly in
Caucasians. Additional studies in larger
sample sizes and stratified by subtype of
skin cancer are still needed, especially
in non-Caucasians. Meanwhile, we
believe that our remarks will contribute
to more accurate elaboration and sub-
stantiation of the results presented by
Jiang et al. (2010).
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TO THE EDITOR
Pseudoxanthoma elasticum (PXE) is an
autosomal recessive disorder character-
ized by ectopic mineralization of soft
connective tissues (Li et al., 2009a;
Uitto et al., 2010). The clinical mani-
festations derive primarily from the
involvement of three organ systems,
the skin, the eyes, and the cardiovas-
cular system. There is considerable
phenotypic, both intra- and inter-
familial, heterogeneity with respect to
the age of onset and the severity of the
disease. Furthermore, in some families
the involvement of one of the organ
systems predominates, so that in some
families the primary manifestations are
in the skin with little eye or cardiovas-
cular involvement, whereas in others,
the ocular problems are the major
cause of morbidity. The eye manifesta-
tions characteristically consist of
angioid streaks that are due to miner-
alization of an elastin-rich Bruch’s
membrane behind the pigmented retina
(Booij et al., 2010). Mineralization of
this membrane causes ruptures of blood
vessels with subsequent neovasculari-
zation, associated with bleeding to
the eye, and leading to progressive loss
of visual acuity and, occasionally,
blindness.
Classic PXE is caused by mutations
in the ABCC6 gene, which encodes a
putative transmembrane transporter
protein, ABCC6, expressed primarily
in the baso-lateral surface of hepato-
cytes (Pfendner et al., 2007). ABCC6
has been shown in in vitro experiments
using inside–out insect cell vesicles to
function as an efflux pump, which
transports anionic small molecular
weight conjugates (Ilia´s et al., 2002).
However, the physiological ligands
in vivo and the precise role of ABCC6
in the pathomechanistic pathways
leading to peripheral connective tissue
mineralization are currently unknown.
Well over 300 distinct mutations
have been identified in the ABCC6
gene, consisting of premature termina-
tion codon (PTC)-causing mutations as
a result of nonsense mutations or out-
of-frame small insertions or deletions
(Pfendner et al., 2007). In addition,
large genomic deletions resulting in loss
of several exons or the entire gene,
and occasionally including flanking
genes as well, have been identified
(Chassaing et al., 2007). Finally, a
number of missense mutations, particu-
larly those affecting the nucleotide
binding folds (NBF1 and NBF2), two
protein domains critical for the function
of ABCC6 as a transmembrane trans-
porter protein, have been identified.
Careful examination of the mutation
database in the context of phenotypic
variability in PXE has not revealed any
clear-cut genotype–phenotype correla-
tions (Pfendner et al., 2007). However,
specific mutations in ABCC6 have beenAbbreviations: PXE, pseudoxanthoma elasticum; PTC, premature termination codon
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recently suggested to be associated with
development of angioid streaks. For
example, the ABCC6 gene in patients
with angioid streaks was scanned for
putative mutations by single-strand
conformation polymorphism techni-
que, and a specific base substitution of
c.G3803A was identified in exon 27,
resulting in a change in codon from
CGG to CAG (p.R1268Q; Mizutani
et al., 2006). Highly significant differ-
ences were observed in both genotype
and in allelic frequencies of p.R1268Q
between patients with angioid streaks
and control subjects (Po0.001,
Po0.002, respectively; w2 test). The
authors concluded that the missense
mutation p.R1268Q is associated with
the disease state of angioid streaks.
Subsequent examination of a cohort
of 54 Japanese patients with angioid
streaks, identified six mutations
(p.R419Q, p.E422K, c.2542delG,
Del_exon23, c.3774-3775insC, and
p.E1427K) as causal mutations for this
eye disease (Sato et al., 2009).
The Molecular Diagnostics Labora-
tory at Jefferson Institute of Molecular
Medicine in Philadelphia has over the
past decade examined patients with PXE
for mutations in ABCC6. On the basis of
the previous suggestions that the
p.R1268Q mutation may be associated
with angioid streaks, we have reviewed
our PXE mutation database, consisting of
a total of 118 individuals with PXE, for
the presence of this missense mutation.
We identified a total of 11 individuals
who were either heterozygous or homo-
zygous for p.R1268Q (Figure 1a and
Table 1). All these individuals had skin
findings consistent with PXE, and in most
cases this diagnosis was confirmed by
skin biopsy, revealing characteristic fea-
tures of PXE, i.e., ectopic mineralization
of pleiomorphic elastic structures in the
mid or upper dermis. All individuals who
had the p.R1268Qmutation also showed
angioid streaks, associated with other
ocular findings, causing considerable
morbidity (blindness, loss of visual acuity;
Figure 1b and Table 1). Examination
of the clinical findings of the remaining
107 patients revealed that, at the time of
DNA testing, 64 (60%) of them had
documented ocular findings. This fre-
quency of ocular involvement differs
from that noted in patients with
p.R1268Q (100%; P¼ 0.0069; Fisher’s
exact test).
One of the diagnostic features of PXE
is that the onset of clinical manifesta-
tions is delayed, and the diagnosis is
often not made until teens or the third
or fourth decade of life. The ocular
manifestations, particularly angioid
streaks, are often accompanied with
PXE, but they are usually noted
later than the cutaneous findings. As
indicated above, a number of specific
mutations in the ABCC6 gene, includ-
ing p.R1268Q, have been suggested
to be associated with angioid streaks.
This specific mutation was initially
identified in families with PXE and
was suggested to be pathogenic
(Ringpfeil et al., 2000). Subsequently,
this mutation was found at the homo-
zygous state in apparently healthy
volunteers, leading the authors to con-
clude that the p.R1268Q mutation in
the ABCC6 gene is an inconsequential
polymorphism, which does not cause
PXE (Germain et al., 2000). The fre-
quency of the p.R1268Q allele in
control population of Caucasian ances-
try was reported to be 0.19 (n¼62;
Germain et al., 2000). At the same time,
the genotypic frequency of homo-
zygous A/A (corresponding to Q) in
Japanese population with angioid
streaks was reported to be 16%
(14/44), whereas in control subjects
the corresponding frequency was
2.1% (3/154; Mizutani et al., 2006). In
our cohort, p.R1268Q substitution was
associated with two other mutations in
the ABCC6 gene in 10 patients, while in
one patient heterozygous for p.R1141X
mutation accompanied p.R1268Q
in trans, and no additional mutations
in this gene could be identified
by complete sequencing of the PCR
products corresponding to all exons
and flanking intronic sequences. This
p.R1268
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Figure 1. Demonstration of the mutation p.R1268Q and conservation of the R1268 in the ABCC6 gene. (a) Genomic DNA was isolated from peripheral blood
leukocytes and used as template for PCR amplification of exon 27 of the gene. Direct sequencing of the PCR product revealed either homozygous or
heterozygous replacement of arginine (R) by glutamine (Q) reflecting G-to-A nucleotide substitution (arrows) at position 3,803 in patients with angioid streaks.
(b) Presentation of angioid streaks in patient AS11 (from Li et al., 2010, with permission). (c) The arginine residue in position 1,268 of the human protein is
conserved in several (mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis familiaris), and chick (Gallus gallus)), but not all (horse (Equus caballus)),
vertebrate proteins. The alignment was performed with the ClustalW2 Program (http://www.ebi.ac.uk/Tools/Clustalw2). H. sapiens, Homo sapiens.
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approach does not exclude the possibi-
lity of a mutation in the regulatory
elements, such as 50 UTR or the
promoter region of ABCC6. It should
be noted that in our cohort of a total of
118 patients with PXE, mutations in the
ABCC6 gene were identified in 104 of
them (88.1%). Finally, it was noted
that arginine in the position 1,268
is conserved in a number of vertebrate
orthologs of the ABCC6 gene
(Figure 1c).
Recent studies have indicated
that another gene, GGCX, encoding
g-glutamyl carboxylase, can harbor
mutations in PXE, either in form of
compound heterozygous missense mu-
tations, or a missense mutation in one
allele of GGCX and a PTC-causing
mutation in one allele of ABCC6
(Vanakker et al., 2007; Li et al.,
2009b, c). Furthermore, recent studies
using the Abcc6/ mice, which reca-
pitulate the genetic, histopathological
and ultrastructural features of PXE, have
suggested the importance of the GGCX
gene as a modulator of the PXE
phenotype (Li and Uitto, 2010). Finally,
it has been suggested that single-
nucleotide polymorphisms in the VEG-
FA gene show significant association
with the development of severe retino-
pathy in patients with PXE (Zarbock
et al., 2009). These findings suggest that
the PXE phenotypes, including the
ocular manifestations, due to mutations
in the ABCC6 gene can be modulated
by genetic factors. Collectively, these
observations and our findings of asso-
ciation of angioid streaks with the
p.R1268Q mutation, suggest that this
sequence variant may contribute to the
development and/or severity of angioid
streaks in patients with PXE due to
mutations in the ABCC6 gene. Early
identification of angioid streaks may
help to prevent development of ocular
complications by allowing institution of
effective therapy to prevent neovascu-
larization, the cause of loss of visual
acuity, and blindness in patients with
PXE (Uitto et al., 2010).
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AS1 67 (M) 179delG G1354R Het AS, moderate–severe visual problems + ND
AS2 45 (M) R1141X NP Het AS, central vision loss due to trauma, macular degeneration NP –
AS3 24 (F) del23-29 1868-5T-G Hom AS, drusen, visual problems + +
AS4 76 (F) 2542delG R419Q Het AS, retinal hemorrhage, cataract, macular degeneration
with neovascularization
+ +
AS5 51 (M) N370D 3107Del3 Het AS + +
AS6 22 (F) G1100E R1339C Het AS + +
AS7 62 (M) del23-29 ? Hom AS, macular degeneration, blindness NP ND
AS8 ? (F) A950T A950T Hom AS + ND
AS9 50 (F) 4063del18 998+2delTG Het AS + ND
AS10 48 (F) G1302R K1490X Het AS, drusen, macular degeneration + +
AS11 18 (F) R1221H R1221H Hom AS + +
Abbreviations: AS, angioid streaks; Het, heterozygous; Hom, homozygous; ND, not done; NP, not present; PXE, pseudoxanthoma elasticum.
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TO THE EDITOR
Xeroderma pigmentosum complemen-
tation group E (XP-E) patients exhibit
sunlight-induced lentiginous pigmen-
tation without blistering on minimal
sun exposure, yet they are prone to
develop multiple skin cancers. Only
eight XP-E patients have been reported
(Bootsma et al., 1970; De Weerd-
Kastelein et al., 1974; Kraemer et al.,
1975; Nichols et al., 1996; Rapic
et al., 1998; Itoh et al., 1999, 2000;
Rapic-Otrin et al., 2003) with mutations
in the DDB2 gene (Tang and Chu,
2002; Itoh, 2006), resulting in the loss
of UV-damaged DNA-binding protein
(UV-DDB) activity (Nichols et al., 2000;
Rapic-Otrin et al., 2003) (Table 1). UV-
DDB is a heterodimer of DDB1 (p127)
and DDB2 (p48) (Keeney et al., 1994;
Kazantsev et al., 1996) that binds with
high affinity to DNA damaged by UV and
is involved in initiation of global genome
nucleotide excision repair (GG-NER)
(Sugasawa, 2010).
We identified four adult XP-E pa-
tients from three kindreds with large
numbers of skin cancers (Table 1).
Patients’ written, informed consent
was obtained. The Declaration of
Helsinki guidelines were followed and
all necessary institutional approvals
were obtained. Patient XP1GO, 45
years old, in family A from Germany
never experienced a blistering sunburn
(Figure 1a). Diagnosed with XP at
age 22, he works as a train conductor.
His first tumor was removed at age 12.
He had 4400 basal cell carcinomas
(BCCs) and squamous cell carcinoma
(SCCs) and 6 melanomas treated by age
30, and now he develops B20 skin
cancers per year. He has no neurologi-
cal abnormalities. Patient XP37BE is a
45-year-old Caucasian female of Dutch
ancestry in family B living in the
western United States (Figure 1b). She
denies ever having a blistering sunburn.
She developed a keratoacanthoma on
her face at 7 years and was diagnosed
with XP. XP37BE has had 4300 BCC
and SCC skin cancers but no melano-
mas. She has no neurological abnorm-
alities. Patient XP66BE is a 43-year-old
brother of XP37BE. He was diagnosed
with XP at age 4 at the same time his
older sister was diagnosed and exhibits
similar clinical symptoms, yet, milder
because of improved sun protection.
Patient XP408BE is a 53-year-old Cau-
casian female in family C from the
eastern United States (Figure 1c). She
had no sunburns and tanned easily, but
did experience significant photophobia.
At age 14, she was found to have
multiple skin cancers (BCCs and SCCs)
on her face and a diagnosis of XP was
made. She has no XP neurological
abnormalities.
All cells were either established at
the Human Genetic Mutant Cell Repo-
sitory, the NCI Repository, or in the
Department of Dermatology, Goettin-
gen, Germany. Plasmid host cell
reactivation assay was performed for
cellular DNA repair capacity measure-
ment (Emmert et al., 2000). The cells
were transfected with a UV-treated
plasmid containing a reporter (lucifer-
ase) gene (pCMVLuc). Compared with
normal and XP variant cells, XP1GO,
XP37BE, XP66BE, and XP408BE/
GM01389 cells had a reduced level of
luciferase expression whereas severe
XP-B control cells had an even lower
level (data not shown). To determine
the complementation group we co-
transfected the UV-irradiated pCMVLuc
with plasmids that carry cloned wild-
type XP complementary DNA (cDNA).
Only co-transfection of the DDB2
cDNA resulted in markedly enhanced
reporter gene activities (data not
shown).
Human primary XP-E fibroblasts have
been reported to show abnormally low
or undetectable levels of p53 and its
downstream-regulated proteins (Hwang
et al., 1999; Itoh et al., 2003; Itoh, 2006).
In agreement with this observation, the
intensities of p53 and p21 bands were
reducedB60–80% and 40–60%, respec-
tively, in untreated XP37BE, XP66BE,
and XP408BE/GM01389 cells (ECL
Abbreviations: BCC, basal cell carcinoma; cDNA, complementary DNA; GG-NER, global genome
nucleotide excision repair; SCC, squamous cell carcinoma; SNP, single-nucleotide polymorphism
STR, short tandem repeat; UV-DDB, UV-damaged DNA-binding protein; XP-E, xeroderma
pigmentosum complementation group E
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